Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

‘Independent’ Drug Safety Office Seen As Goal of Senate Vioxx Investigation

By Pharmaceutical Processing | November 22, 2004

WASHINGTON, DC (November 22, 2004) – The idea of an “independent” drug safety office in the Food & Drug Administration (FDA) merits consideration, Office of New Drugs Acting Director Dr. Sandra Kweder said during the Senate Finance Committee hearing November 18 on Merck’s withdrawal of Vioxx.

“It is an idea worth looking carefully at,” Kweder said. “How it would operate, what kind of resources it would take, absolutely it’s worth looking at.”

The influential journal on prescription pharmaceuticals and biotechnology, The Pink Sheet (www.thepinksheet.com), reported that at the outset of the hearing Committee Chairman Chuck Grassley (R-Iowa) and Ranking Minority Member Max Baucus (D-Montana) declared support for an independent drug safety office, and the first panel of witnesses echoed that call.

Baucus asked Kweder to explain why creating an independent safety office would be a bad idea.

Kweder noted that a planned Institute of Medicine study of FDA’s safety review process would assess that question.

Baucus, however, pressed Kweder for an immediate opinion, saying he did not want to wait for “another study.” Kweder responded that her personal opinion is that, while “our system works very well… I don’t have any objection…to an independent Office of Drug Safety.”

“There is clearly concern by some members of the public, by members of the committee, that somehow the system is not working as well as it could without that independence. And if that’s the concern, we need to assess that,” Kweder said.

Grassley’s declaration of support for changes in structure of FDA’s regulation of drugs gives a clear focus for the Finance Committee’s investigation of the agency, beyond his desire to provide a forum for dissenters within government agencies to be heard, The Pink Sheet report said.

The Vioxx hearing primarily served as a platform for Office of Drug Safety (ODS) Associate Director for Science David Graham to offer his concerns about FDA’s approach to drug safety regulation. He described FDA as “incapable of protecting America against another Vioxx” without structural changes.

The two witnesses who testified alongside Graham – Stanford University School of Medicine Adjunct Clinical Professor Dr. Gurkirpal Singh and University of Washington Medicine & Epidemiology Professor Dr. Bruce Psaty, PhD – also endorsed the creation of an independent drug safety office.

Graham’s discussion of the drugs that he considers to have unresolved safety issues became the headline event of the hearing – and underscores the reasons why manufacturers are not eager to see independence for drug safety reviews, The Pink Sheet report continued.

Following the hearing, the FDA issued a statement by Center for Drug Evaluation & Research Acting Director Dr. Steven Galson disputing Graham’s characterization of the role of ODS, saying the ODS “is already an independent office separate from the Office of New Drugs.”

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE